Literature DB >> 18387400

Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.

M Babjuk1, V Soukup, M Pesl, M Kostírová, E Drncová, H Smolová, M Szakacsová, R Getzenberg, I Pavlík, J Dvorácek.   

Abstract

OBJECTIVES: To compare results of urinary cytology, quantitative detection of human complement factor H-related protein (BTA TRAK), and urinary fragments of cytokeratins 8 and 18 (UBC IRMA) with the recurrence status in patients with pTapT1 bladder cancer and to define the possible role of these methods in a surveillance protocol.
METHODS: We collected urine from 88 consecutive patients with primary pTapT1 tumors before the first transurethral resection (TURB) and before each follow-up cystoscopy. In all samples urinary cytology and quantitative BTA and UBC tests were performed. We compared results with recurrence status and with tumor characteristics in the case of recurrence. We constructed receiver operator characteristic (ROC) curves for quantitative methods. In addition, we evaluated individual cutoffs based on pretreatment levels.
RESULTS: During the mean follow-up of 16.96 months, we performed 313 cystoscopies, 93 of which were positive in 51 patients. The sensitivity and specificity of cytology, BTA, and UBC were 19.8% and 99%, 53.8% and 83.9%, and 12.1% and 97.2%, respectively. The sensitivity of pTis detection was 66.6%, 0%, and 100%, respectively. With cutoffs set to a sensitivity of 90%, the specificity of BTA and UBC dropped to 24.8% and 20.4%, respectively. Individually calculated cutoffs did not provide a significant benefit.
CONCLUSIONS: Because of high specificity and sensitivity in pTis detection, urinary cytology fulfills requirements for an adjunctive method to cystoscopy. Quantitative BTA and UBC tests have a low sensitivity in the detection of bladder cancer recurrence and cannot be used routinely to reduce the number of cystoscopies during follow-up.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18387400     DOI: 10.1016/j.urology.2007.12.021

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  13 in total

Review 1.  Current Use and Promise of Urinary Markers for Urothelial Cancer.

Authors:  William Tabayoyong; Ashish M Kamat
Journal:  Curr Urol Rep       Date:  2018-10-17       Impact factor: 3.092

2.  Urine cytology and adjunct markers for detection and surveillance of bladder cancer.

Authors:  Peggy S Sullivan; Jessica B Chan; Mary R Levin; Jianyu Rao
Journal:  Am J Transl Res       Date:  2010-07-25       Impact factor: 4.060

Review 3.  High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.

Authors:  Oscar Rodriguez Faba; Joan Palou; Alberto Breda; H Villavicencio
Journal:  World J Urol       Date:  2012-10-16       Impact factor: 4.226

Review 4.  Urinary proteomic profiling for diagnostic bladder cancer biomarkers.

Authors:  Steve Goodison; Charles J Rosser; Virginia Urquidi
Journal:  Expert Rev Proteomics       Date:  2009-10       Impact factor: 3.940

5.  Urothelial Bladder Cancer Urinary Biomarkers.

Authors:  Aidan P Noon; Alexandre R Zlotta
Journal:  EJIFCC       Date:  2014-04-28

6.  Gene expression profiling in bladder cancer identifies potential therapeutic targets.

Authors:  Syed A Hussain; Daniel H Palmer; Wing-Kin Syn; Joseph J Sacco; Richard M D Greensmith; Taha Elmetwali; Vijay Aachi; Bryony H Lloyd; Puthen V Jithesh; John Arrand; Darren Barton; Jawaher Ansari; D Ross Sibson; Nicholas D James
Journal:  Int J Oncol       Date:  2017-03-02       Impact factor: 5.650

Review 7.  A review on the accuracy of bladder cancer detection methods.

Authors:  Chao-Zhe Zhu; Hua-Nong Ting; Kwan-Hoong Ng; Teng-Aik Ong
Journal:  J Cancer       Date:  2019-07-08       Impact factor: 4.207

8.  Urinary markers for bladder cancer.

Authors:  Zachary L Smith; Thomas J Guzzo
Journal:  F1000Prime Rep       Date:  2013-07-01

Review 9.  An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer.

Authors:  Francesco Soria; Michael J Droller; Yair Lotan; Paolo Gontero; David D'Andrea; Kilian M Gust; Morgan Rouprêt; Marek Babjuk; Joan Palou; Shahrokh F Shariat
Journal:  World J Urol       Date:  2018-06-21       Impact factor: 4.226

Review 10.  Molecular markers in bladder cancer.

Authors:  Francesco Soria; Laura-Maria Krabbe; Tilman Todenhöfer; Jakub Dobruch; Anirban P Mitra; Brant A Inman; Kilian M Gust; Yair Lotan; Shahrokh F Shariat
Journal:  World J Urol       Date:  2018-09-26       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.